Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success * with the GORE ® CARDIOFORM ASD Occluder, and consistent safety outcomes † across a broad range of ASD ...

FLAGSTAFF, Arizona, Oct. 2, 2019 /PRNewswire/ -- W. L. Gore & Associates (Gore) has introduced the newest member of its family of occluders, the GORE® CARDIOFORM ASD Occluder, which has received CE ...

FLAGSTAFF, Ariz., June 4, 2019 /PRNewswire/ -- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder ...

FLAGSTAFF, Ariz.--W. L. Gore & Associates today reported the first patient enrolled in the GORE® Septal Occluder Clinical Study evaluating the safety and efficacy of the new GORE Septal Occluder in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio W.L. Gore and Associates announced its ...

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) has completed enrollment for the pivotal phase of the Gore ASSURED Clinical Study. This investigational device exemption (IDE) ...

Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

The US Food and Drug Administration (FDA) has approved the Gore Cardioform septal occluder for closure of patent foramen ovale (PFO) to prevent recurrent ischemic stroke, the manufacturer, WL Gore & ...

At 2-year follow-up, a septal occluder device was deemed safe and effective for transcatheter closure of atrial septal defects, according to new data published in Circulation: Cardiovascular ...